Efficacy and safety of dapagliflozin according to baseline blood pressure - observations from DECLARE-TIMI 58 Trlial

被引：0
|
作者：
Furtado, R. [1 ]
Raz, I [2 ]
Goodrich, E. L. [3 ]
Sabatine, M. S. [3 ]
Wiviott, S. D. [3 ]
机构：
[1] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
[2] Hebrew Univ Jerusalem, Hadassah Med Ctr, Diabet Unit, Jerusalem, Israel
[3] Harvard Med Sch, Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3063 / 3063
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
    Furtado, Remo H. M.
    Raz, Itamar
    Goodrich, Erica L.
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Aylward, Philip
    Dalby, Anthony J.
    Dellborg, Mikael
    Dimulescu, Doina
    Nicolau, Jose C.
    Oude Ophuis, Anthonius J. M.
    Cahn, Avivit
    Mosenzon, Ofri
    Gause-Nilsson, Ingrid
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2022, 145 (21) : 1581 - 1591
  • [2] Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
    Cahn, Avivit
    Mosenzon, Ofri
    Wiviott, Stephen D.
    Rozenberg, Aliza
    Yanuv, Ilan
    Goodrich, Erica L.
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Johansson, Peter A.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Raz, Itamar
    DIABETES CARE, 2020, 43 (02) : 468 - 475
  • [3] Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
    Pollack, Rena
    Raz, Itamar
    Wiviott, Stephen D.
    Goodrich, Erica L.
    Murphy, Sabina A.
    Yanuv, Ilan
    Rozenberg, Aliza
    Mosenzon, Ofri
    Langkilde, Anna Maria
    Gause-Nilsson, Ingrid A. M.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Sabatine, Marc S.
    Cahn, Avivit
    DIABETES CARE, 2023, 46 (01) : 156 - 164
  • [4] The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
    Mosenzon, Ofri
    Wiviott, Stephen D.
    Heerspink, Hiddo J. L.
    Dwyer, Jamie P.
    Cahn, Avivit
    Goodrich, Erica L.
    Rozenberg, Aliza
    Schechter, Meir
    Yanuv, Ilan
    Murphy, Sabina A.
    Zelniker, Thomas A.
    Gause-Nilsson, Ingrid A. M.
    Langkilde, Anna Maria
    Fredriksson, Martin
    Johansson, Peter A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Sabatine, Marc S.
    Raz, Itamar
    DIABETES CARE, 2021, 44 (08) : 1805 - 1815
  • [5] DECLARE-TIMI 58: Participants' baseline characteristics
    Raz, Itamar
    Mosenzon, Ofri
    Bonaca, Marc P.
    Cahn, Avivit
    Kato, Eri T.
    Silverman, Michael G.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Langkilde, Anna M.
    Johansson, Peter A.
    Sabatine, Marc S.
    Wiviott, Stephen D.
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1102 - 1110
  • [6] DECLARE-TIMI 58: Design and Baseline Characteristics
    Raz, Itamar
    Bonaca, Marc P.
    Mosenzon, Ofri
    Kato, Eri T.
    Cahn, Avivit
    Silverman, Michael G.
    Bhatt, Deepak L.
    Leiter, Lawrence
    Mcguire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Langkilde, Anna Maria
    Johansson, Peter A.
    Sabatine, Marc S.
    Wiviott, Stephen D.
    DIABETES, 2017, 66 : A333 - A333
  • [7] The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbAlc: Analyses from DECLARE-TIMI 58
    Cahn, Avivit
    Wiviott, Stephen D.
    Mosenzon, Ofri
    Murphy, Sabina
    Goodrich, Erica L.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Mcguire, Darren K.
    Wilding, John
    Gause-Nilsson, Ingrid A.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Raz, Itamar
    DIABETES, 2021, 70
  • [8] Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58
    Cahn, Avivit
    Wiviott, Stephen D.
    Mosenzon, Ofri
    Murphy, Sabina
    Goodrich, Erica L.
    Yanuv, Ilan
    Rozenberg, Aliza
    Wilding, John
    Leiter, Lawrence A.
    Bhatt, Deepak L.
    Mcguire, Darren K.
    Litwak, Leon
    Kooy, Adriaan
    Gause-Nilsson, Ingrid A.
    Fredriksson, Martin
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Raz, Itamar
    DIABETES, 2020, 69
  • [9] Baseline characteristics of the DECLARE-TIMI 58 trial population
    Raz, I.
    Bonaca, M. P.
    Mosenzon, O.
    Kato, E. T.
    Cahn, A.
    Silverman, M. G.
    Bhatt, D. L.
    Leiter, L.
    McGuire, D. K.
    Wilding, J. P.
    Gause-Nilsson, I. A. M.
    Langkilde, A.
    Johansson, P. A.
    Sabatine, M. S.
    Wiviott, S. D.
    DIABETOLOGIA, 2017, 60 : S519 - S520
  • [10] The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial
    O'Donoghue, Michelle L.
    Kato, Eri T.
    Mosenzon, Ofri
    Murphy, Sabina A.
    Cahn, Avivit
    Marmolejo, Marisol H.
    Tankova, Tsvetalina
    Smahelova, Alena
    Merlini, Piera A.
    Gause-Nilsson, Ingrid A.
    Langkilde, Anna Maria
    McGuire, Darren K. K.
    Wilding, John
    Leiter, Lawrence A.
    Bhatt, Deepak L.
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2019, 140
12345